Skip Navigation


CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable podcast. CIT can also broadcast NIH-only or HHS-only content.

NIH Consensus Development Conference: Inhaled Nitric Oxide Therapy For Premature Infants - Day 1

Loading video...

 
   
Air date: Wednesday, October 27, 2010, 8:30:00 AM
Time displayed is Eastern Time, Washington DC Local
Views:
Category: Conferences
Runtime: 06:26:19
Description: Babies born before the 28th week of pregnancy—more than 30,000 per year in the United States—are particularly vulnerable to breathing problems due to their underdeveloped lungs. Nitric oxide is sometimes used to treat infants with severe breathing problems, and inhaled nitric oxide therapy was approved by the U.S. FDA in 2000 to treat term and near-term infants (born after the 33rd week of pregnancy) with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born at less than 34 weeks’ gestation. The National Institutes of Health is convening a Consensus Development Conference October 27-29, 2010 to assess the available scientific evidence related to the benefits and risks of inhaled nitric oxide therapy for premature infants.
Debug: Show Debug
NLM Title: NIH Consensus Development Conference : inhaled nitric oxide therapy for premature infants [electronic resource] / NICHD and OMAR.
Series: Inhaled nitric oxide therapy for premature infants
Author: National Institute of Child Health and Human Development (U.S.)
Publisher:
Other Title(s): Inhaled nitric oxide therapy for premature infants
Abstract: (CIT): Babies born before the 28th week of pregnancy--more than 30,000 per year in the United States--are particularly vulnerable to breathing problems due to their underdeveloped lungs. Nitric oxide is sometimes used to treat infants with severe breathing problems, and inhaled nitric oxide therapy was approved by the U.S. FDA in 2000 to treat term and near-term infants (born after the 33rd week of pregnancy) with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born at less than 34 weeks" gestation. The National Institutes of Health is convening a Consensus Development Conference October 27-29, 2010 to assess the available scientific evidence related to the benefits and risks of inhaled nitric oxide therapy for premature infants.
Subjects: Infant, Newborn
Infant, Premature, Diseases--therapy
Nitric Oxide--therapeutic use
Respiratory Tract Diseases--therapy
Publication Types: Congresses
Consensus Development Conference, NIH
Webcasts
Download: To download this event, select one of the available bitrates:
[256k]  [512k]    How to download a Videocast
NLM Classification: WS 480
NLM ID: 101549229
CIT Live ID: 9498
Permanent link: http://videocast.nih.gov/launch.asp?16237